$725 Million is the total value of SPHERA FUNDS MANAGEMENT LTD.'s 110 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | SPDR SERIES TRUSTput | $71,393,000 | – | 750,000 | +100.0% | 9.84% | – | |
| GILD | New | GILEAD SCIENCES INC | $25,148,000 | – | 355,000 | +100.0% | 3.47% | – |
| New | ISHARES TRput | $24,566,000 | – | 150,000 | +100.0% | 3.39% | – | |
| ALNY | New | ALNYLAM PHARMACEUTICALS INC | $19,228,000 | – | 195,232 | +100.0% | 2.65% | – |
| AMGN | New | AMGEN INC | $18,459,000 | – | 100,000 | +100.0% | 2.54% | – |
| BLUE | New | BLUEBIRD BIO INC | $11,376,000 | – | 72,483 | +100.0% | 1.57% | – |
| SODA | New | SODASTREAM INTERNATIONAL LTD | $6,292,000 | – | 73,762 | +100.0% | 0.87% | – |
| AGLE | New | AEGLEA BIOTHERAPEUTICS INC | $5,386,000 | – | 509,118 | +100.0% | 0.74% | – |
| ZFGN | New | ZAFGEN INC | $4,910,000 | – | 480,000 | +100.0% | 0.68% | – |
| AUTL | New | AUTOLUS THERAPEUTICS PLCspon ads | $4,716,000 | – | 176,045 | +100.0% | 0.65% | – |
| SESN | New | SESEN BIO INC | $4,635,000 | – | 2,377,068 | +100.0% | 0.64% | – |
| WAB | New | WABTEC CORP | $4,590,000 | – | 46,564 | +100.0% | 0.63% | – |
| ARPO | New | AERPIO PHARMACEUTICALS INC | $4,580,000 | – | 1,103,554 | +100.0% | 0.63% | – |
| SRRK | New | SCHOLAR ROCK HLDG CORP | $4,430,000 | – | 283,997 | +100.0% | 0.61% | – |
| CSCO | New | CISCO SYS INC | $4,303,000 | – | 100,000 | +100.0% | 0.59% | – |
| EPZM | New | EPIZYME INC | $4,162,000 | – | 307,154 | +100.0% | 0.57% | – |
| SBBP | New | STRONGBRIDGE BIOPHARMA PLC | $4,044,000 | – | 673,996 | +100.0% | 0.56% | – |
| XENE | New | XENON PHARMACEUTICALS INC | $4,039,000 | – | 439,034 | +100.0% | 0.56% | – |
| KZR | New | KEZAR LIFE SCIENCES INC | $3,943,000 | – | 227,900 | +100.0% | 0.54% | – |
| VRTX | New | VERTEX PHARMACEUTICALS INC | $3,399,000 | – | 20,000 | +100.0% | 0.47% | – |
| WIX | New | WIX COM LTD | $2,963,000 | – | 29,542 | +100.0% | 0.41% | – |
| ELOX | New | ELOXX PHARMACEUTICALS INC | $2,859,000 | – | 167,474 | +100.0% | 0.39% | – |
| FSCT | New | FORESCOUT TECHNOLOGIES INC | $2,617,000 | – | 76,400 | +100.0% | 0.36% | – |
| VRCA | New | VERRICA PHARMACEUTICALS INC | $2,482,000 | – | 125,800 | +100.0% | 0.34% | – |
| APTX | New | APTINYX INC | $2,477,000 | – | 102,474 | +100.0% | 0.34% | – |
| APLS | New | APELLIS PHARMACEUTICALS INC | $2,438,000 | – | 110,803 | +100.0% | 0.34% | – |
| MRVL | New | MARVELL TECHNOLOGY GROUP LTDord | $2,355,000 | – | 109,842 | +100.0% | 0.32% | – |
| KRNT | New | KORNIT DIGITAL LTD | $2,329,000 | – | 130,831 | +100.0% | 0.32% | – |
| TBIO | New | TRANSLATE BIO INC | $1,645,000 | – | 130,000 | +100.0% | 0.23% | – |
| PTLA | New | PORTOLA PHARMACEUTICALS INC | $1,385,000 | – | 120,000 | +100.0% | 0.19% | – |
| ZYME | New | ZYMEWORKS INC | $1,091,000 | – | 73,800 | +100.0% | 0.15% | – |
| MRTX | New | MIRATI THERAPEUTICS INC | $707,000 | – | 14,335 | +100.0% | 0.10% | – |
| TCDA | New | TRICIDA INC | $610,000 | – | 20,410 | +100.0% | 0.08% | – |
| BMRN | New | BIOMARIN PHARMACEUTICAL INC | $589,000 | – | 6,250 | +100.0% | 0.08% | – |
| AUDC | New | AUDIOCODES LTDord | $461,000 | – | 59,226 | +100.0% | 0.06% | – |
| CISN | New | CISION LTD | $224,000 | – | 15,000 | +100.0% | 0.03% | – |
| EIDX | New | EIDOS THERAPEUTICS INC | $220,000 | – | 10,828 | +100.0% | 0.03% | – |
| KMPH | New | KEMPHARM INC | $147,000 | – | 22,622 | +100.0% | 0.02% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-08-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICAL-SP ADR | 36 | Q3 2023 | 8.4% |
| MERCK & CO INC NEW | 35 | Q3 2023 | 8.4% |
| NICE Systems Ltd | 27 | Q3 2023 | 4.4% |
| BIOGEN INC | 26 | Q3 2023 | 6.7% |
| AMICUS THERAPEUTICS INC | 26 | Q2 2022 | 4.3% |
| PFIZER INC | 25 | Q3 2023 | 9.2% |
| SAREPTA THERAPEUTICS INC | 25 | Q3 2023 | 3.2% |
| JOHNSON & JOHNSON | 24 | Q3 2023 | 8.0% |
| UNIQURE NV | 23 | Q3 2023 | 1.2% |
| SYNDAX PHARMACEUTICALS INC | 22 | Q3 2023 | 3.9% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cyclacel Pharmaceuticals, Inc. | February 06, 2023 | 250,000 | 2.0% |
| Altimmune, Inc. | February 14, 2022 | 1,244,241 | 3.1% |
| Allot Ltd. | February 16, 2021 | 1,129,054 | 3.2% |
| Larimar Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Neos Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Orgenesis Inc. | February 16, 2021 | 525,216 | 0.0% |
| Sio Gene Therapies Inc. | February 16, 2021 | ? | ? |
| X4 Pharmaceuticals, Inc | February 16, 2021 | 250,000 | 0.0% |
| Axovant Gene Therapies Ltd. | February 25, 2020 | 2,931,017 | 8.0% |
| Axovant Gene Therapies Ltd. | February 11, 2020 | 398,540 | 1.8% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-02-15 |
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-08 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-10 |
| SC 13G | 2023-08-30 |
View SPHERA FUNDS MANAGEMENT LTD.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.